Find Funding Opportunities

This Notice of Funding Opportunity Announcement (NOFO), issued by the National Institutes of Health (NIH) invites eligible United States small businesses to submit Small Business Technology Transfer (STTR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this NOFO are encouraged to submit STTR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement does not accept clinical trials.

The purpose of this Notice of Funding Opportunity (NOFO) is to support the NeuroImaging Tools and Resources Collaboratory and to enable collaborative research in neuroimaging informatics. The competition is limited to the U24 awardees and subawardees of RFA-EB-16-002.

Changing the first receipt date from 9/6/23 to 11/15/23.

This Notice of Funding Opportunity (NOFO) supports the optimization of promising genome editing-based therapeutic leads for Alzheimer's Disease-Related Dementias (ADRD), towards IND-enabling studies. Specifically, it supports the characterization and optimization of therapeutic lead(s) that show promise as potential genome editing therapeutics, as evidenced by convincing proof-of-concept studies in appropriate models. At the end of the funding period, successful projects will have optimized a genome editing therapeutic candidate with demonstrated bioactivity, manufacturability, biodistribution, in vivo efficacy, and/or target engagement (measurement of proximal downstream effects) and optimal dosing, combined with other properties consistent with the desired clinical application. This NOFO is not specific for any one or group within the ADRD spectrum of disorders. Disorders include; Frontotemporal dementia (FTD), Lewy body dementias (LBD) (including Dementia with Lewy bodies (DLB), Parkinson Disease Dementia (PDD)), Vascular contributions to Cognitive Impairment and Dementia (VCID), and Multiples Etiology Dementias (MED).

The purpose of this Notice of Funding Opportunity (NOFO) is toinvite applications that aggregate and analyze existing data in the COVID-19 Neuro Databank-Biobank (NeuroCOVIDProject).TheNeuroCOVIDProject was establishedin 2020 to serve as a robust national resource to understand theneurological complicationsassociated with COVID-19 and the effects of COVID-19 on pre-existing neurological conditions. The NeuroCOVID Project has collected and curated a wide range of data from the United States and international sites. This NOFO encourages hypothesis-driven applications to further scientific knowledge of neurological complications ofCOVID-19 by using this de-identified database. Thedata may be combined with data from other U.S. and International databases for analyses.However,collection of new primary data from those affected by COVID-19 or comparison cohorts isNOT covered by this NOFO.

Since 2017, the National Institute on Aging has sponsored a successful Administrative Supplement program to stimulate the field of Alzheimers disease (AD) and its related dementias (ADRD) (e.g., frontotemporal dementia, Lewy body dementia, Vascular Contributions to Cognitive Impairment and Dementia (VCID), and multiple etiology dementias) (NOT-AG-22-025, NOT-AG-21-018; NOT-AG-20-034; NOT-AG-17-008). This program has especially been effective in bringing researchers into the AD/ADRD research realm. Once more, the participating Institutes and Centers (ICs) are inviting supplement applications to take advantage of this opportunity to support the value of their projects, consistent with the previously peer-reviewed objectives. Therefore, as administrative supplements, the work proposed must be within the scope of the research or training that is already supported in order to be considered for funding. Active awards with project end dates in FY 2025 or later are eligible. The award may not be in a terminal no-cost extension or going into a no-cost extension in FY 2024. Please note that a few ICs limit no-cost extensions in the final non-competing year of an award. For that reason, it is important to contact staff at the IC supporting the award when planning the request.

The purpose of this Funding Opportunity Announcement (FOA) is to support a Chemical Exposure Resource and Coordination Core (ExRC) that will provide infrastructure, management, and research support for studies of Chemicals of Concern (CoC) to the Chemical Countermeasures Research Program (CCRP). This core, established across diverse geographical regions, is intended to support multidisciplinary CCRP investigators, through development of infrastructure and exposure protocols for selected toxicants. The ExRC will provide facility access for using diverse models to characterize pathophysiological mechanisms and evaluating potential medical countermeasures through early-stage development efforts supported by the CCRP.

The ultimate goal is to develop multi-target disease-modifying therapeutics based on an appreciation of the complex interaction of pathways, cells, circuits, systems or pathologies that are present in complex AD/ADRD diagnoses. Such therapeutics could be a single drug or biologic targeting multiple pathways, cell, circuits, systems or pathologies, or could be a combination of therapies. While hundreds of possible targets have been suggested for AD alone, theres a need to better understand how multiple targets might interact in a synergistic way that would allow us to tackle AD/ADRD from multiple fronts in a single person, akin to what has been successful in infectious disease or cancer. This FOA will support applications that test hypotheses of possible beneficial interactions of known targets as well as understanding the mechanisms of interaction in the R61. The R33 would support rigorous validation of the proposed multi-target approach (one drug or biologic targeting multiple pathways; and/or a combination of therapies) to support future multi-target therapy development efforts. Successful grantees will be in position to apply for IGNITE or other similar translational grant mechanisms.

Goal is to have experimental models that can accurately reproduce neuropathological signatures and clinically relevant neurodegenerative, biochemical and behavioral sequelae as those seen in human subjects post-TBI AD/ADRDs. Requirement: Interdisciplinary Team science approach / consortium type of applications. Applications will include multiple sites (3-5 sites) developing and/or testing specific models that will then implement a test of reproducibility across the consortium. Requirement: Must have a clinician with expertise in post-TBI ADRD on the team. Encourage having neuropathologists as consultants on grants. Requirement: Models developed through this FOA will be required to share their model, model details and related standards with the VA-funded interagency preclinical resource center - PRECISE TBI Studies investigating neurodegeneration of white matter and chronic inflammation in post-TBI AD/ADRDs are highly encouraged. Innovative applications reaching beyond the current AD/ADRD models are highly encouraged.

The National Institutes of Health (NIH) intends to support the development of innovative methods for quantitative evaluation of myofascial tissues for pain management involving research participants using a two-phase grant funding mechanism. This effort is part of the NIH HEALSM (Helping to End Addiction Long-term) Initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative is bolstering research across NIH to (1) improve treatment and prevention of opioid misuse and opioid use disorder and (2) enhance pain management. This notice of funding opportunity (NOFO) seeks research applications to develop quantitative measures of myofascial tissues and assess their abilities to detect changes to myofascial tissues across a variety of pain management interventions. Candidate objective measures may be based on minimally invasive imaging technologies, electrophysiological recordings, integration of multiparametric imaging and electrophysiology approaches, or their integration with other markers (e.g., immune factors, genomic markers, physiological factors) through multiscale modeling or machine learning analysis. The first phase, funded by the R61, will provide funding for up to 3 years to develop quantitative measures that can differentiate abnormal myofascial tissue from healthy tissues using cross-sectional correlations with clinical signs/symptoms. In addition, the R61 phase should include planning activities for the R33 phase. The second phase, funded under the R33, will provide support to assess the abilities of the quantitative measures developed in the R61 phase to measure tissue changes in response to therapies or manipulations that may relieve pain using rigorous, longitudinal clinical study design. The combined R61/R33 should not exceed 5 years. Transition from the R61 to the R33 phase of the award will be administratively reviewed and will be determined based on successful co